First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes
Kurs
+0,43%
Likviditet
0,20 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-21 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | N/A | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2025-05-15 | N/A | Årsstämma |
| 2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2025-02-13 | - | Extra Bolagsstämma 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-20 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-09 | - | Årsstämma |
| 2023-05-30 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-10 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2022-06-09 | - | Årsstämma |
| 2022-04-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-03 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2020-06-02 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2019-06-11 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-12 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-10-23 | - | Extra Bolagsstämma 2017 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-13 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2017-06-12 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-11-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2016-05-26 | - | Årsstämma |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-06 | - | Extra Bolagsstämma 2016 |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Nanexa AB today announces that the company's Phase 1 study for type 2 diabetes has been initiated with dosing of the first patient. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa's patented PharmaShell® system within the NEX-22 project. The study is a dose-escalation study aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses.
The study is being conducted in Germany by the CRO Profil and is the first clinical study to investigate a long-acting formulation of a GLP-1 compound based on PharmaShell. The study is an open-label phase 1 study where the long-acting formulation is administered by subcutaneous injection. The study is designed to include several consecutive groups with escalating doses. The study includes both women and men with type 2 diabetes. The results of the study will provide important information for optimization of the formulation for future regulatory pharmacokinetic and efficacy studies in patients with type 2 diabetes.
"This study is an important milestone for NEX-22 and Nanexa. A long-acting drug improves patient compliance and has the potential to increase efficacy and safety as well as reduce the environmental impact of single-use devices. We are pleased to partner with Profil, which has particular expertise in clinical trials in diabetes and obesity,” says Göran Ando, Chairman of the Board of Nanexa.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs for the treatment of type 2 diabetes and obesity. As the prevalence of obesity and type 2 diabetes increases worldwide, the market for GLP-1 receptor agonists is also growing. In a recent report, GlobalData estimates that sales of GLP-1 receptor agonists for the type 2 diabetes and obesity markets will reach over $125 billion by 2033 (1).
Nanexa believes that the increased convenience of fewer injections than current options makes its formulation an attractive treatment option for the majority of patients.
References
1. 68 market forecast för "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast, Global Data, May 2024
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company’s Certified Adviser is Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).